Masashi Takeuchi, Hideaki Obara, Hirofumi Kawakubo, Masahiro Shinoda, Koji Okabayashi, Shuhei Mayanagi, Tomoyuki Irino, Kazumasa Fukuda, Rieko Nakamura, Norihito Wada, Minoru Kitago, Hiroshi Yagi, Yuta Abe, Go Oshima, Shutaro Hori, Masashi Tsuruta, Takashi Ishida, Takahiro Yokose, Kazuya Hirukawa, Yoh Isobe, Yasuhito Sekimoto, Hirohisa Harada, Yusuke Maeda, Masaya Shito, Takayuki Kondo, Yasunori Sato, Yuko Kitagawa
Journal: BMJ open 2020;9(5):e028269
PMID: 31142533
INTRODUCTION
The prevalence of surgical site infection (SSI) remains higher in gastrointestinal surgery than in other surgeries. Although several guidelines have indicated the efficacy of chlorhexidine and povidone-iodine in reducing the SSI rate, the optimal recommendation has still not been established. Therefore, it is necessary to determine the more effective antiseptic for surgical site preparation. Olanexidine (1.5% olanedine, Otsuka Pharmaceutical Factory, Tokushima, Japan), which is a new antiseptic in Japan, has antimicrobial activity against a wide range of bacteria, including Gram-positive and Gram-negative bacteria. Our study will contribute to determining a new antiseptic for use in gastrointestinal and other surgeries.
METHODS AND ANALYSIS
We propose a multicentre, randomised controlled clinical trial for comparing two treatments, that is, 1.5% olanexidine or 10% povidone-iodine, for surgical skin preparation to prevent SSI in clean-contaminated gastrointestinal surgeries with surgical wounds. Patients aged ≥20 years at the time of consent will be included. The primary outcome measure is the 30-day postoperative SSI rate. For the primary analysis, which is aimed at comparing the treatment effects, the adjusted risk ratio and its 95% CI will be estimated using the Mantel-Haenszel method.
ETHICS AND DISSEMINATION
The protocol was first approved by the Institutional Review Board of Keio University School of Medicine, followed by the institutional review board of each participating site. Participant recruitment began in June 2018. The final results will be published in international peer-reviewed medical journals.
TRIAL REGISTRATION NUMBER
UMIN 000031560; Pre-results.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Full Text Sources:
Molecular Biology Databases:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.